The Discovery Of Bioactive Ingredients Of Dandelion And The Exploring Of Their Mechanism Treated On Breast Cancer Cells MCF-7

Breast cancer is one of the most common cancers among women. The researchabout bioactive compounds of dandelion, the common traditional herb used foragainst breast cancer was limited. The discovery and exploring of bioactivecompounds of dandelion is significant for treating breast cancer. Besides, novelapproaches for discovery of bioactive compounds in herbs has been developed, whichcould bring new ideas for the research of other herbs.Firstly, a bioactivity-oriented fractionation screening strategy based on UrinePharmacology has been developed for quickly identify bioactive anti-breast cancerconstituents of Dandelion. The urine of SD rats was used for the research after theextracts of dandelion were treated on them. About11fractions of dandelion-containedurine were separated by the semi-preparative-HPLC. These fractions were used forthe MTT assay and it indicated that three fractions (the first, fifth and sixth fractions)had significant inhibition effect on MCF-7cells. Then the bioactive fractions wereanalyzed by the UPLC-MS.Secondly, five potential bioactive compounds were analyzed by MTT assay andcell cycle assay. About five concentrations were used for the cell viability assay. TheMTT assay indicated that these five compounds all have a block effect on MCF-7cellsin a concentration-and time-dependent manner. The cell cycle assay alsoaffirmed the results of MTT assay.Finally, luteolin and lupeol were choosed to do further research about inhibitingbreast cancer MCF-7cells. The objective of this research is to investigate the suppressive effects of luteolin and lupeol on the breast cancer MCF-7cells, andexplore their mechanism on inhibiting the proliferation of MCF-7cells based on cellmetabonomics and cell cycle. Gas chromatography mass spectrometry (GC-MS) wasused in the cell metabonomics assay to identify metabolites of MCF-7cells andMCF-7cells treated with lupeol and luteolin. Then, Principal component analysis(PCA) and Partial least square discriminant analysis (PLS-DA) were used to processthe metabolic data.Metabonomics result reveals that the metabolites of MCF-7cells and MCF-7cells treated with luteolin were obviously different. The10metabolites such asD-Galactose、D-Ribose which had a significant contribution to classification wereselected and preliminarily identified due to the accurate mass. Since cells in phase ofS were increased significantly, we speculate that luteolin has a blocking effect onpentose phosphate pathway of MCF-7cells, which contributes to its inhibition effecton proliferation of MCF-7cells.Metabonomics result also reveals that the metabolitesof MCF-7cells and MCF-7cells treated with lupeol have significant differences.11metabolites such as butanedioic acid, phosphoric acid, L-Leucine and Isoleucinewhich had a significant contribution to classification were selected and preliminarilyidentified. Since cells in phase of G1were increased significantly after the treatmentof lupeol, we speculated that lupeol has a blocking effect on the generation ofsuccinyl-CoA and the reaction of substrate phosphorylation of tricarboxylic acid cycleof MCF-7cells. This study provided novel approaches to the mechanism research onlupeol treating on breast cancer cells MCF-7based on cell metabonomics.